Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis

European Journal of Pain (United Kingdom)

Volumn 18, Issue 10, 2014, Pages 1480-1489

  Coelho, A ^a,b   Oliveira, R ^a   Rossetto, O ^c   Cruz, C D ^a,b   Cruz, F ^b,d   Avelino, A ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PADOVA   (Italy)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CYCLOPHOSPHAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROMODULIN; PROTEIN C FOS; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; ACETYLCHOLINE RELEASE INHIBITOR; SNAP25 PROTEIN, RAT;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLADDER FUNCTION; CONTROLLED STUDY; CYSTALGIA; CYSTITIS; CYSTOMETRY; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; IMMUNOHISTOCHEMISTRY; MICTURITION REFLEX; MOTOR ACTIVITY; NONHUMAN; OVERACTIVE BLADDER; PAIN ASSESSMENT; PROTEIN EXPRESSION; RAT; ANIMAL; BLADDER; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INTERSTITIAL CYSTITIS; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; NOCICEPTION; NOCICEPTIVE PAIN; PATHOPHYSIOLOGY; SPINAL CORD;

ACETYLCHOLINE RELEASE INHIBITORS; ANIMALS; BOTULINUM TOXINS, TYPE A; CALCITONIN GENE-RELATED PEPTIDE; CYCLOPHOSPHAMIDE; CYSTITIS, INTERSTITIAL; DISEASE MODELS, ANIMAL; GAP-43 PROTEIN; IMMUNOHISTOCHEMISTRY; INJECTIONS, SPINAL; MITOGEN-ACTIVATED PROTEIN KINASES; NOCICEPTION; NOCICEPTIVE PAIN; PROTO-ONCOGENE PROTEINS C-FOS; RATS; SPINAL CORD; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; URINARY BLADDER;

EID: 84908481214     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/ejp.513     Document Type: Article

References (34)

1. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., Wein, A.,; Standardisation Sub-committee of the International Continence Society (2002). The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21, 167-178.
2. Antonucci, F., Rossi, C., Gianfranceschi, L., Rossetto, O., Caleo, M., (2008). Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28, 3689-3696.
3. Auge, C., Chene, G., Dubourdeau, M., Desoubzdanne, D., Corman, B., Palea, S., Lluel, P., Vergnolle, N., Coelho, A.M., (2013). Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Eur J Pharmacol 707, 32-40.
4. Avelino, A., Cruz, F., Coimbra, A., (1999). Intravesical resiniferatoxin desensitizes rat bladder sensory fibres without causing intense noxious excitation. A c-fos study. Eur J Pharmacol 378, 17-22.
5. Bach-Rojecky, L., Lackovic, Z., (2009). Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 94, 234-238.
6. Bach-Rojecky, L., Salkovic-Petrisic, M., Lackovic, Z., (2010). Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol 633, 10-14.
7. Benowitz, L.I., Routtenberg, A., (1997). GAP-43: An intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20, 84-91.
8. Boucher, M., Meen, M., Codron, J.P., Coudore, F., Kemeny, J.L., Eschalier, A., (2000). Cyclophosphamide-induced cystitis in freely-moving conscious rats: Behavioral approach to a new model of visceral pain. J Urol 164, 203-208.
9. Chapple, C., Sievert, K.D., MacDiarmid, S., Khullar, V., Radziszewski, P., Nardo, C., Thompson, C., Zhou, J., Haag-Molkenteller, C., (2013). OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur Urol 64, 249-256.
10. Coelho, A., Cruz, F., Cruz, C.D., Avelino, A., (2012). Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 61, 1178-1184.
11. Cruz, C.D., Avelino, A., McMahon, S.B., Cruz, F., (2005). Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. Eur J Neurosci 21, 773-781.
12. Cruz, C.D., McMahon, S.B., Cruz, F., (2006). Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Exp Neurol 200, 66-73.
13. Cruz, F., Herschorn, S., Aliotta, P., Brin, M., Thompson, C., Lam, W., Daniell, G., Heesakkers, J., Haag-Molkenteller, C., (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol 60, 742-750.
14. Cui, M., Khanijou, S., Rubino, J., Aoki, K.R., (2004). Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107, 125-133.
15. Frias, B., Allen, S., Dawbarn, D., Charrua, A., Cruz, F., Cruz, C.D., (2013). Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience 234, 88-102.
16. Giannantoni, A., Bini, V., Dmochowski, R., Hanno, P., Nickel, J.C., Proietti, S., Wyndaele, J.J., (2012). Contemporary management of the painful bladder: A systematic review. Eur Urol 61, 29-53.
17. Lee, W.H., Shin, T.J., Kim, H.J., Lee, J.K., Suh, H.W., Lee, S.C., Seo, K., (2011). Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice. Anesth Analg 112, 228-235.
18. Lucioni, A., Bales, G.T., Lotan, T.L., McGehee, D.S., Cook, S.P., Rapp, D.E., (2008). Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101, 366-370.
19. Ma, J., Shen, J., Lee, C.A., Elsaidi, G.A., Smith, T.L., Walker, F.O., Rushing, J.T., Tan, K.H., Koman, L.A., Smith, B.P., (2005). Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: A study in rats. J Orthop Res 23, 302-309.
20. Marinelli, S., Luvisetto, S., Cobianchi, S., Makuch, W., Obara, I., Mezzaroma, E., Caruso, M., Straface, E., Przewlocka, B., Pavone, F., (2010). Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 171, 316-328.
21. Marinelli, S., Vacca, V., Ricordy, R., Uggenti, C., Tata, A.M., Luvisetto, S., Pavone, F., (2012). The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS ONE 7, e47977.
22. Matak, I., Bach-Rojecky, L., Filipovic, B., Lackovic, Z., (2011). Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186, 201-207.
23. Morenilla-Palao, C., Planells-Cases, R., Garcia-Sanz, N., Ferrer-Montiel, A., (2004). Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279, 25665-25672.
24. Neugebauer, V., Rumenapp, P., Schaible, H.G., (1996). Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn-neurons during development of acute inflammation. Neuroscience 71, 1095-1109.
25. Pinto, R., Lopes, T., Frias, B., Silva, A., Silva, J.A., Silva, C.M., Cruz, C., Cruz, F., Dinis, P., (2010). Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58, 360-365.
26. Restani, L., Antonucci, F., Gianfranceschi, L., Rossi, C., Rossetto, O., Caleo, M., (2011). Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 31, 15650-15659.
27. Restani, L., Novelli, E., Bottari, D., Leone, P., Barone, I., Galli-Resta, L., Strettoi, E., Caleo, M., (2012). Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 13, 1083-1089.
28. Saitoh, C., Yokoyama, H., Chancellor, M.B., de Groat, W.C., Yoshimura, N., (2010). Comparison of voiding function and nociceptive behavior in two rat models of cystitis induced by cyclophosphamide or acetone. Neurourol Urodyn 29, 501-505.
29. Santos-Silva, A., da Silva, C.M., Cruz, F., (2013). Botulinum toxin treatment for bladder dysfunction. Int J Urol 20, 956-962.
30. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.Y., White, D.J., Hartenstein, V., Eliceiri, K., Tomancak, P., Cardona, A., (2012). Fiji: An open-source platform for biological-image analysis. Nat Methods 9, 676-682.
31. Sun, R.Q., Lawand, N.B., Lin, Q., Willis, W.D., (2004). Role of calcitonin gene-related peptide in the sensitization of dorsal horn neurons to mechanical stimulation after intradermal injection of capsaicin. J Neurophysiol 92, 320-326.
32. van de Merwe, J.P., Nordling, J., Bouchelouche, P., Bouchelouche, K., Cervigni, M., Daha, L.K., Elneil, S., Fall, M., Hohlbrugger, G., Irwin, P., Mortensen, S., van Ophoven, A., Osborne, J.L., Peeker, R., Richter, B., Riedl, C., Sairanen, J., Tinzl, M., Wyndaele, J.J., (2008). Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur Urol 53, 60-67.
33. Vizzard, M.A., (2001). Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis. J Chem Neuroanat 21, 125-138.
34. Vizzard, M.A., Boyle, M.M., (1999). Increased expression of growth-associated protein (GAP-43) in lower urinary tract pathways following cyclophosphamide (CYP)-induced cystitis. Brain Res 844, 174-187.